{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:49:40Z","timestamp":1791913780310,"version":"4.3.4"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:00:00Z","timestamp":1791849600000},"content-version":"vor","delay-in-days":89,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Medications for opioid use disorder (MOUD) reduce overdose risk and improve outcomes, yet receipt remains low in acute care settings, including among patients engaged in health care. Understanding sociodemographic and clinical factors associated with lower odds of MOUD receipt is essential to inform strategies that expand access and strengthen responses to the opioid epidemic in the United States.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To describe sociodemographic and clinical characteristics and estimate factors associated with lower odds of MOUD receipt among patients with opioid-related diagnoses (ORD) care involvement who had an assigned primary care provider and who utilized acute care settings within a large academic health system in Southern California.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We analyzed electronic health records from 4,242 patients who had\u2009\u2265\u20091 acute care encounter and a UC San Diego Health-assigned primary care provider between April 22, 2022, and April 21, 2025. Patients were classified as having ORD clinical involvement if they had a documented ICD-10 ORD, an MOUD prescription within 6 months prior to the index acute care encounter, an MOUD prescription during the index acute care encounter, or an opioid overdose-related encounter. Descriptive statistics characterized the sample; logistic regression estimated odds of limited MOUD receipt.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Among patients with opioid-related involvement who had an assigned primary care provider and utilized acute care services, 428 (10.1%) received MOUD during the acute care encounter. Prior MOUD prescription within six months preceding the index acute care encounter was associated with the highest odds of MOUD receipt (aOR\u2009=\u200924.11, 95% CI [18.60, 31.53],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Having other substance-related diagnoses was also associated with higher odds of MOUD receipt (aOR\u2009=\u20091.85, 95% CI [1.29, 2.69],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). In contrast, patients with any mental health diagnosis had lower odds of MOUD receipt (aOR\u2009=\u20090.73, 95% CI [0.57, 0.94],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.02). Although overdose-related encounters were associated with lower odds of MOUD receipt (aOR\u2009=\u20090.56, 95% CI [0.29, 1.00],\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.06), the association did not reach statistical significance after adjustment.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Significant gaps persist in MOUD receipt among patients with opioid-related involvement in acute care settings. Prior MOUD prescription was strongly associated with MOUD receipt, suggesting barriers in receipt among patients without previous prescriptions. Patients with mental health comorbidity had lower odds of MOUD receipt. Although overdose-related encounters were associated with lower adjusted odds of MOUD receipt, additional research is needed to better understand barriers to MOUD initiation following overdose-related encounters. Overall, these findings call for tailored strategies such as addiction consultation services, peer navigation programs, integrated addiction and behavioral health services, and low-barrier MOUD initiation protocols within acute care settings.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13722-026-00703-0","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T20:25:38Z","timestamp":1784233538000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A missed opportunity: receipt of medication for opioid use disorder in Southern California acute care settings"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6698-815X","authenticated-orcid":false,"given":"Brian","family":"Maila","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3909-3318","authenticated-orcid":false,"given":"Carla","family":"Marienfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"703_CR1","unstructured":"National Institute on Drug Abuse. Medications for opioid use disorder | National Institute on Drug Abuse (NIDA) [Internet]; 2025 [cited 2025 Dec 16]. Available from: https:\/\/nida.nih.gov\/research-topics\/medications-opioid-use-disorder."},{"key":"703_CR2","doi-asserted-by":"publisher","unstructured":"Kepner W, Courchesne-Krak NS, Satybaldiyeva N, Narasimhan R, Marienfeld CB. Emergency care utilization in persons with substance related diagnoses. Addict Behav Rep. 2024;20. https:\/\/doi.org\/10.1016\/j.abrep.2024.100573.","DOI":"10.1016\/j.abrep.2024.100573"},{"key":"703_CR3","doi-asserted-by":"publisher","unstructured":"Maila B, Z\u00fa\u00f1iga ML, Marienfeld C. Sociodemographic and clinical characteristics associated with overdose among patients with a substance-related diagnosis in the emergency department of Southern California. Harm Reduct J. 2025;22(1). https:\/\/doi.org\/10.1186\/S12954-025-01233-9. PubMed PMID: 40410736.","DOI":"10.1186\/S12954-025-01233-9"},{"issue":"8","key":"703_CR4","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1001\/jamainternmed.2024.1733","volume":"184","author":"CM Jones","year":"2024","unstructured":"Jones CM, Shoff C, Blanco C, Losby JL, Ling SM, Compton WM, Overdose. Behavioral Health Services, and Medications for Opioid Use Disorder After a Nonfatal Overdose. JAMA Intern Med. 2024;184(8):954. 10.1001\/. JAMAINTERNMED.2024.1733 PubMed PMID: 38884975.","journal-title":"JAMA Intern Med"},{"issue":"11","key":"703_CR5","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMOA2401177","volume":"391","author":"J Samet","year":"2024","unstructured":"Samet J, El-Bassel N, Winhusen T, Jackson R, Oga E, Chandler R, et al. Community-Based Cluster-Randomized Trial to Reduce Opioid Overdose Deaths. N Engl J Med. 2024;391(11):989\u20131001. https:\/\/doi.org\/10.1056\/NEJMOA2401177. PubMed PMID: 38884347.","journal-title":"N Engl J Med"},{"key":"703_CR6","doi-asserted-by":"publisher","unstructured":"Gaiazov S, Mullen W, Wheeler A, Munnangi S, Gu Y, DeKoven M, et al. Factors associated with emergency room visits among patients with opioid use disorder: a study of buprenorphine-treated and untreated patients. Drug Alcohol Depend Rep. 2025;16. https:\/\/doi.org\/10.1016\/j.dadr.2025.100349.","DOI":"10.1016\/j.dadr.2025.100349"},{"key":"703_CR7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j","author":"A Manhapra","year":"2017","unstructured":"Manhapra A, Rosenheck R, Fiellin DA. Opioid substitution treatment is linked to reduced risk of death in opioid use disorder. BMJ. 2017. https:\/\/doi.org\/10.1136\/bmj.j. 1947 PubMed PMID: 28446438. 357:j1947.","journal-title":"BMJ"},{"key":"703_CR8","doi-asserted-by":"publisher","first-page":"100744","DOI":"10.1016\/j.lanwpc.2023.100744","volume":"34","author":"CH Saing","year":"2023","unstructured":"Saing CH. OAT and NSP and their potential to reduce HIV incidence among people who inject drugs in low- and middle-income countries. Lancet Reg Health West Pac. 2023;34:100744. https:\/\/doi.org\/10.1016\/j.lanwpc.2023.100744.","journal-title":"Lancet Reg Health West Pac"},{"issue":"7","key":"703_CR9","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1111\/hiv.13636","volume":"25","author":"ME Socias","year":"2024","unstructured":"Socias ME, Cui Z, Le Foll B, Lei J, Stewart S, Anand R, et al. Sexually transmitted and blood-borne infection risk reduction with methadone and buprenorphine\/naloxone among people with prescription-type opioid use disorder: Findings from a Canadian pragmatic randomized trial. HIV Med. 2024;25(7):817\u201325. https:\/\/doi.org\/10.1111\/hiv.13636. PubMed PMID: 38506171.","journal-title":"HIV Med"},{"key":"703_CR10","doi-asserted-by":"publisher","first-page":"117822182211383","DOI":"10.1177\/11782218221138335","volume":"16","author":"TE Moses","year":"2022","unstructured":"Moses TE, Rhodes GL, Tavakoli E, Christensen CW, Amirsadri A, Greenwald MK. Predictors of Retention and Drug Use Among Patients With Opioid Use Disorder Transferred to a Specialty Second Chance Methadone Program. Subst Abuse. 2022;16:11782218221138336. https:\/\/doi.org\/10.1177\/11782218221138335. PubMed PMID: 36407024.","journal-title":"Subst Abuse"},{"issue":"11","key":"703_CR11","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1001\/jamapediatrics.2018.2143","volume":"172","author":"SE Hadland","year":"2018","unstructured":"Hadland SE, Bagley SM, Rodean J, Silverstein M, Levy S, Larochelle MR, et al. Receipt of Timely Addiction Treatment and Association of Early Medication Treatment with Retention in Care among Youths with Opioid Use Disorder. JAMA Pediatr. 2018;172(11):1029\u201337. https:\/\/doi.org\/10.1001\/jamapediatrics.2018.2143. PubMed PMID: 30208470.","journal-title":"JAMA Pediatr"},{"key":"703_CR12","doi-asserted-by":"publisher","first-page":"j1550","DOI":"10.1136\/bmj.j1550","volume":"357","author":"L Sordo","year":"2017","unstructured":"Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550. https:\/\/doi.org\/10.1136\/bmj.j1550. PubMed PMID: 28446428.","journal-title":"BMJ"},{"issue":"1","key":"703_CR13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/ADM.0000000000001392","volume":"19","author":"SN Koerber","year":"2025","unstructured":"Koerber SN, Huynh D, Farrington S, Springer K, Manteuffel J. Disparities in Buprenorphine Administration for Opioid Use Disorder in the Emergency Department. J Addict Med. 2025;19(1):89\u201394. 10.1097. \/ADM.0000000000001392 PubMed PMID: 39514889.","journal-title":"J Addict Med"},{"issue":"5","key":"703_CR14","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.annemergmed.2018.11","volume":"73","author":"AA Herring","year":"2019","unstructured":"Herring AA, Perrone J, Nelson LS. Managing Opioid Withdrawal in the Emergency Department With Buprenorphine. Ann Emerg Med. 2019;73(5):481\u20137. https:\/\/doi.org\/10.1016\/j.annemergmed.2018.11.032 PubMed PMID: 30616926.","journal-title":"Ann Emerg Med"},{"issue":"1","key":"703_CR15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/J.JEN.2020.10.001","volume":"47","author":"TD Strout","year":"2021","unstructured":"Strout TD, Baumann MR, Wendell LT, Understanding ED. Buprenorphine Initiation for Opioid Use Disorder: A Guide for Emergency Nurses. J Emerg Nurs. 2021;47(1):139\u201354. https:\/\/doi.org\/10.1016\/J.JEN.2020.10.001. PubMed PMID: 33390217.","journal-title":"J Emerg Nurs"},{"issue":"2","key":"703_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jemermed","volume":"64","author":"R Childers","year":"2023","unstructured":"Childers R, Castillo EM, Cronin AO, Swee S, Lasoff D. Emergency Department-Initiated Buprenorphine Treatment in a Population with a High Rate of Homelessness: An Observational Study. J Emerg Med. 2023;64(2):129\u201335. https:\/\/doi.org\/10.1016\/j.jemermed. 2022.12.004 PubMed PMID: 36806434.","journal-title":"J Emerg Med"},{"issue":"5","key":"703_CR17","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.5811\/WESTJEM","volume":"21","author":"KT LeSaint","year":"2020","unstructured":"LeSaint KT, Klapthor B, Wang RC, Geier C. Buprenorphine for Opioid Use Disorder in the Emergency Department: A Retrospective Chart Review. West J Emerg Med. 2020;21(5):1175\u201381. https:\/\/doi.org\/10.5811\/WESTJEM. 2020.6.46452 PubMed PMID: 32970572.","journal-title":"West J Emerg Med"},{"key":"703_CR18","unstructured":"DHCS. Current projects - DHCS opioid response [Internet]; 2023 [cited 2026 Mar 27]. Available from: https:\/\/californiaopioidresponse.org\/projects\/current-projects\/."},{"key":"703_CR19","unstructured":"DHCS. California Department of Health Care Services. California bridge program: expanding access to medication for addiction treatment in emergency departments [Internet]; 2023 [cited 2026 Mar 27]. Available from: https:\/\/californiaopioidresponse.org\/matproject\/california-bridge-program\/."},{"key":"703_CR20","doi-asserted-by":"publisher","DOI":"10.1007\/S11606-024-09008-X","author":"R Shearer","year":"2024","unstructured":"Shearer R, Englander H, Hagedorn H, Fawole A, Laes JA, Titus H, et al. Hospital Provider\u2019s Perspectives on MOUD Initiation and Continuation After Inpatient Discharge. J Gen Intern Med. 2024. https:\/\/doi.org\/10.1007\/S11606-024-09008-X. PubMed PMID: 39586949.","journal-title":"J Gen Intern Med"},{"issue":"1","key":"703_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S43058-024-00649-X\/TABLES\/1","volume":"5","author":"O Ajumobi","year":"2024","unstructured":"Ajumobi O, Friedman S, Granner M, Lucero J, Westhoff J, Koch B, et al. Emergency department buprenorphine program: staff concerns and recommended implementation strategies. Implement Sci Commun. 2024;5(1):1\u20139. https:\/\/doi.org\/10.1186\/S43058-024-00649-X\/TABLES\/1. PubMed PMID: 39334346.","journal-title":"Implement Sci Commun"},{"issue":"9","key":"703_CR22","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1377\/HLTHAFF.2025.01002","volume":"44","author":"DE Metz","year":"2025","unstructured":"Metz DE, The Editorial Staff. Insights About The Opioid Crisis. Health Aff. 2025;44(9):1029\u20131029. https:\/\/doi.org\/10.1377\/HLTHAFF.2025.01002.","journal-title":"Health Aff"},{"issue":"9","key":"703_CR23","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1111\/acem.70035","volume":"32","author":"N Chhabra","year":"2025","unstructured":"Chhabra N, Smith D, Parde N, Hsing-Smith N, Bianco JM, Taylor RA, et al. Racial, ethnic, and sex disparities in buprenorphine treatment from emergency departments by discharge diagnosis. Acad Emerg Med. 2025;32(9):985\u201393. https:\/\/doi.org\/10.1111\/acem.70035. PubMed PMID: 40277252.","journal-title":"Acad Emerg Med"},{"issue":"4","key":"703_CR24","doi-asserted-by":"publisher","first-page":"710","DOI":"10.5811\/WESTJEM.58636","volume":"24","author":"J Papp","year":"2023","unstructured":"Papp J, Emerman C. Disparities in Emergency Department Naloxone and Buprenorphine Initiation. West J Emerg Med. 2023;24(4):710\u20136. 10. 5811\/WESTJEM.58636 PubMed PMID: 37527392.","journal-title":"West J Emerg Med"},{"issue":"4","key":"703_CR25","doi-asserted-by":"publisher","first-page":"S118","DOI":"10.1016\/j.annemergmed.2024.08.256","volume":"84","author":"E Bastian","year":"2024","unstructured":"Bastian E, Matts S, Oh Y, Reed E, Siff J, Wilson L, et al. 253 Prescribing Patterns and Patient Factors in an Emergency Department-Initiated MOUD Program to Combat Opioid Use Disorder Throughout a Changing Landscape. Ann Emerg Med. 2024;84(4):S118. https:\/\/doi.org\/10.1016\/j.annemergmed.2024.08.256.","journal-title":"Ann Emerg Med"},{"key":"703_CR26","doi-asserted-by":"publisher","first-page":"108583","DOI":"10.1016\/j.drugalcdep.2021.108583","volume":"221","author":"P Lagisetty","year":"2021","unstructured":"Lagisetty P, Garpestad C, Larkin A, Macleod C, Antoku D, Slat S, et al. Identifying individuals with opioid use disorder: Validity of International Classification of Diseases diagnostic codes for opioid use, dependence and abuse. Drug Alcohol Depend. 2021;221:108583. J.DRUGALCDEP.2021.108583 PubMed PMID: 33662670.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"703_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13722-023-00405","volume":"18","author":"JF Scherrer","year":"2023","unstructured":"Scherrer JF, Sullivan MD, LaRochelle MR, Grucza R. Validating opioid use disorder diagnoses in administrative data: a commentary on existing evidence and future directions. Addict Sci Clin Pract. 2023;18(1):1\u20135. https:\/\/doi.org\/10.1186\/S13722-023-00405-. X\/METRICS PubMed PMID: 37592369.","journal-title":"Addict Sci Clin Pract"},{"issue":"188","key":"703_CR28","first-page":"1","volume":"1","author":"DG White","year":"2021","unstructured":"White DG, Adams NB, Brown AM, O\u2019Jiaku-Okorie A, Badwe R, Shaikh S, et al. Enhancing Identification of Opioid-involved Health Outcomes Using National Hospital Care Survey Data. Vital Health Stat. 2021;1(188):1\u201331. PubMed PMID: 34662270.","journal-title":"Vital Health Stat"},{"issue":"3","key":"703_CR29","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/j.amepre.2024.12.001","volume":"68","author":"A Board","year":"2025","unstructured":"Board A, Vivolo-Kantor A, Kim SY, Tran EL, Thomas SA, Terplan M, et al. Using ICD Codes Alone May Misclassify Overdoses Among Perinatal People. Am J Prev Med. 2025;68(3):563\u201370. https:\/\/doi.org\/10.1016\/j.amepre.2024.12.001. PubMed PMID: 39645154.","journal-title":"Am J Prev Med"},{"key":"703_CR30","doi-asserted-by":"publisher","unstructured":"Brown AM, White DG, Adams NB, Badwe R, Shaikh S, Guluma L. Validation of the enhanced opioid identification and co-occurring disorders algorithms data evaluation and methods research [Internet]. 2024 Jan. https:\/\/doi.org\/10.15620\/cdc:134958.","DOI":"10.15620\/cdc:134958"},{"key":"703_CR31","unstructured":"Stokes E, Liu S, Smith H, Lyons BC, Krishnan S. CDC all drug overdose v3 parsed drug overdose surveillance and epidemiology (DOSE) system guidance syndromic surveillance definition factsheet and technical brief [Internet]. 2024 Jan 16 [cited 2025 Oct 15]. Available from: https:\/\/knowledgerepository.syndromicsurveillance.org\/cdc-all-drug-v2."},{"issue":"5","key":"703_CR32","doi-asserted-by":"publisher","first-page":"770","DOI":"10.17269\/S41997-024-00915-4\/TABLES\/4","volume":"115","author":"FIN Mbutiwi","year":"2024","unstructured":"Mbutiwi FIN, Yapo APJ, Toirambe SE, Rees E, Plouffe R, Carabin H. Sensitivity and specificity of International Classification of Diseases algorithms (ICD-9 and ICD-10) used to identify opioid-related overdose cases: A systematic review and an example of estimation using Bayesian latent class models in the absence of gold standards. Can J Public Health. 2024;115(5):770\u201383. https:\/\/doi.org\/10.17269\/S41997-024-00915-4\/TABLES\/4. PubMed PMID: 39085747.","journal-title":"Can J Public Health"},{"issue":"7","key":"703_CR33","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1093\/pm\/pnaf019","volume":"26","author":"RW Hurley","year":"2025","unstructured":"Hurley RW, Bland KT, Chaskes MD, Hill EL, Adams MCB. Diagnosis and coding of opioid misuse: a systematic scoping review and implementation framework. Pain Med. 2025;26(7):372\u201396. 10.1093\/. PM\/PNAF019 PubMed PMID: 40036760.","journal-title":"Pain Med"},{"key":"703_CR34","unstructured":"IBM Corp. IBM SPSS Statistics for Windows, Version 30.0 [Internet]. Armonk, NY: IBM Corp.; 2023 [cited 2026 May 15]. Available from: https:\/\/lib-software.sdsu.edu\/software\/spss."},{"key":"703_CR35","unstructured":"R Core Team. R: A language and environment for statistical computing [Internet]. Vienna, Austria; 2026 [cited 2026 May 15]. Available from: https:\/\/www.r-project.org\/."},{"key":"703_CR36","doi-asserted-by":"publisher","first-page":"100031","DOI":"10.1016\/j.dadr.2022.100031","volume":"2","author":"CD Nordeck","year":"2022","unstructured":"Nordeck CD, Welsh C, Schwartz RP, Mitchell SG, O\u2019Grady KE, Gryczynski J. Opioid agonist treatment initiation and linkage for hospitalized patients seen by a substance use disorder consultation service. Drug Alcohol Depend Rep. 2022;2:100031. 10.1016\/. J.DADR.2022.100031 PubMed PMID: 36845893.","journal-title":"Drug Alcohol Depend Rep"},{"issue":"5","key":"703_CR37","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1097\/ADM.0000000000000611","volume":"14","author":"H Englander","year":"2020","unstructured":"Englander H, King C, Nicolaidis C, Collins D, Patten A, Gregg J, et al. Predictors of Opioid and Alcohol Pharmacotherapy Initiation at Hospital Discharge Among Patients Seen by an Inpatient Addiction Consult Service. J Addict Med. 2020;14(5):415\u201322. 10. 1097\/ADM.0000000000000611 PubMed PMID: 31868830.","journal-title":"J Addict Med"},{"issue":"2","key":"703_CR38","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s11606-023-08420-z","volume":"39","author":"HJ Mosher","year":"2024","unstructured":"Mosher HJ, Hadlandsmyth K, Alexander B, Lund BC. Continuation of Buprenorphine During Hospitalization and Subsequent Retention in Therapy: an Observational Study in Veterans Administration Hospitals. J Gen Intern Med. 2024;39(2):207\u201313. 08420-Z PubMed PMID: 37752303.","journal-title":"J Gen Intern Med"},{"key":"703_CR39","doi-asserted-by":"publisher","unstructured":"Cook RR, Foot C, Arah OA, Humphreys K, Rudolph KE, Luo SX, et al. Estimating the impact of stimulant use on initiation of buprenorphine and extended-release naltrexone in two clinical trials and real-world populations. Addict Sci Clin Pract. 2023;18(1). https:\/\/doi.org\/10.1186\/S13722-023-00364-3. PubMed PMID: 36788634.","DOI":"10.1186\/S13722-023-00364-3"},{"key":"703_CR40","doi-asserted-by":"publisher","unstructured":"Smart R, Kim JY, Kennedy S, Tang L, Allen L, Crane D, et al. Association of polysubstance use disorder with treatment quality among Medicaid beneficiaries with opioid use disorder. J Subst Abuse Treat. 2023;144. https:\/\/doi.org\/10.1016\/J.JSAT.2022.108921.\u00a0PubMed PMID: 36327615.","DOI":"10.1016\/J.JSAT.2022.108921"},{"key":"703_CR41","doi-asserted-by":"publisher","unstructured":"Russell C, Law J, Imtiaz S, Rehm J, Le Foll B, Ali F. The impact of methamphetamine use on medications for opioid use disorder (MOUD) treatment retention: a scoping review. Addict Sci Clin Pract. 2023;18(1). https:\/\/doi.org\/10.1186\/S13722-023-00402-0. PubMed PMID: 37587456.","DOI":"10.1186\/S13722-023-00402-0"},{"issue":"2","key":"703_CR42","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1177\/29767342231221060","volume":"45","author":"RD Shearer","year":"2024","unstructured":"Shearer RD, Hernandez E, Beebe TJ, Virnig BA, Bart G, Winkelman TNA, et al. Providers\u2019 Experiences and Perspectives in Treating Patients With Co-Occurring Opioid and Stimulant Use Disorders in the Hospital. Subst use Addict J. 2024;45(2):250. https:\/\/doi.org\/10.1177\/29767342231221060.\u00a0PubMed PMID: 38258816.","journal-title":"Subst use Addict J"},{"issue":"3","key":"703_CR43","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/S10597-024-01345-9","volume":"61","author":"G Victor","year":"2025","unstructured":"Victor G, Kheibari A, Strickland JC. Exploring the Lived Experiences of Medication for Opioid use Disorder Treatment: A Qualitative Study among a Crowdsourced Convenience Sample. Community Ment Health J. 2025;61(3):411\u20139. https:\/\/doi.org\/10.1007\/S10597-024-01345-9. PubMed PMID: 39235576.","journal-title":"Community Ment Health J"},{"key":"703_CR44","doi-asserted-by":"publisher","unstructured":"Fredericksen RJ, Baker R, Sibley A, Estadt AT, Colston D, Mixson LS, et al. Motivation and context of concurrent stimulant and opioid use among persons who use drugs in the rural United States: a multi-site qualitative inquiry. Harm Reduct J. 2024;21(1). https:\/\/doi.org\/10.1186\/S12954-024-00986-Z. PubMed PMID: 38561753.","DOI":"10.1186\/S12954-024-00986-Z"},{"key":"703_CR45","doi-asserted-by":"publisher","first-page":"108921","DOI":"10.1016\/j.jsat.2022.108921","volume":"144","author":"R Smart","year":"2023","unstructured":"Smart R, Kim JY, Kennedy S, Tang L, Allen L, Crane D, et al. Association of polysubstance use disorder with treatment quality among Medicaid beneficiaries with opioid use disorder. J Subst Abuse Treat. 2023;144:108921.JSAT.2022.108921 PubMed PMID: 36327615.","journal-title":"J Subst Abuse Treat"},{"issue":"1","key":"703_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13722-023-00364-3\/FIGURES\/3","volume":"18","author":"RR Cook","year":"2023","unstructured":"Cook RR, Foot C, Arah OA, Humphreys K, Rudolph KE, Luo SX, et al. Estimating the impact of stimulant use on initiation of buprenorphine and extended-release naltrexone in two clinical trials and real-world populations. Addict Sci Clin Pract. 2023;18(1):1\u201314. https:\/\/doi.org\/10.1186\/S13722-023-00364-3\/FIGURES\/3. PubMed PMID: 36788634.","journal-title":"Addict Sci Clin Pract"},{"issue":"9","key":"703_CR47","doi-asserted-by":"publisher","first-page":"e2435603","DOI":"10.1001\/jamanetworkopen.2024.35603","volume":"7","author":"N Chhabra","year":"2024","unstructured":"Chhabra N, Smith D, Dickinson G, Caglianone L, Taylor RA, D\u2019Onofrio G, et al. Trends and Disparities in Initiation of Buprenorphine in US Emergency Departments, 2013\u20132022. JAMA Netw Open. 2024;7(9):e2435603. 10.1001. \/JAMANETWORKOPEN.2024.35603 PubMed PMID: 39325455.","journal-title":"JAMA Netw Open"},{"issue":"6","key":"703_CR48","doi-asserted-by":"publisher","first-page":"e2215287","DOI":"10.1001\/jamanetworkopen.2022.15287","volume":"5","author":"MA Stevens","year":"2022","unstructured":"Stevens MA, Tsai J, Savitz ST, Nath B, Melnick ER, D\u2019Onofrio G, et al. Trends and Disparities in Access to Buprenorphine Treatment Following an Opioid-Related Emergency Department Visit Among an Insured Cohort, 2014\u20132020. JAMA Netw Open. 2022;5(6):e2215287\u20132215287. 10.1001. \/JAMANETWORKOPEN.2022.15287 PubMed PMID: 35657629.","journal-title":"JAMA Netw Open"},{"issue":"3","key":"703_CR49","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/M17-3107","volume":"169","author":"MR Larochelle","year":"2018","unstructured":"Larochelle MR, Bernson D, Land T, Stopka TJ, Wang N, Xuan Z, et al. Medication for Opioid Use Disorder After Nonfatal Opioid Overdose and Association With Mortality: A Cohort Study. Ann Intern Med. 2018;169(3):137\u201345. 10. 7326\/M17-3107 PubMed PMID: 29913516.","journal-title":"Ann Intern Med"},{"issue":"5","key":"703_CR50","doi-asserted-by":"publisher","first-page":"e205852","DOI":"10.1001\/jamanetworkopen.2020.5852","volume":"3","author":"AS Kilaru","year":"2020","unstructured":"Kilaru AS, Kilaru AS, Xiong A, Lowenstein M, Meisel ZF, Perrone J, et al. Incidence of Treatment for Opioid Use Disorder Following Nonfatal Overdose in Commercially Insured Patients. JAMA Netw Open. 2020;3(5):e205852\u2013205852. 10.1001. \/JAMANETWORKOPEN.2020.5852 PubMed PMID: 32459355.","journal-title":"JAMA Netw Open"},{"key":"703_CR51","doi-asserted-by":"publisher","first-page":"100195","DOI":"10.1016\/J.DADR.2023.100195","volume":"9","author":"KY Xu","year":"2023","unstructured":"Xu KY, Huang V, Williams AR, Martin CE, Bazazi AR, Grucza RA. Co-occurring psychiatric disorders and disparities in buprenorphine utilization in opioid use disorder: An analysis of insurance claims. Drug Alcohol Depend Rep. 2023;9:100195. https:\/\/doi.org\/10.1016\/J.DADR.2023.100195.","journal-title":"Drug Alcohol Depend Rep"},{"key":"703_CR52","doi-asserted-by":"publisher","first-page":"108405","DOI":"10.1016\/j.jsat.2021.108405","volume":"130","author":"M Robbins","year":"2021","unstructured":"Robbins M, Haroz R, Mazzarelli A, Clements D, Jones CW, Salzman M. Buprenorphine use and disparities in access among emergency department patients with opioid use disorder: A cross-sectional study. J Subst Abuse Treat. 2021;130:108405. https:\/\/doi.org\/10.1016\/j.jsat.2021.108405. PubMed PMID: 34118697.","journal-title":"J Subst Abuse Treat"},{"issue":"8","key":"703_CR53","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/ajad.12644","volume":"26","author":"M Litz","year":"2017","unstructured":"Litz M, Leslie D. The impact of mental health comorbidities on adherence to buprenorphine: A claims based analysis. Am J Addict. 2017;26(8):859\u201363. 10. 1111\/AJAD.12644 PubMed PMID: 29143483.","journal-title":"Am J Addict"},{"key":"703_CR54","doi-asserted-by":"publisher","unstructured":"Krawczyk N, Eisenberg M, Schneider KE, Richards TM, Lyons BC, Jackson K, et al. Predictors of overdose death among high-risk emergency department patients with substance-related encounters: a data linkage cohort study. Ann Emerg Med. 2020;75(1):1\u201312. https:\/\/doi.org\/10.1016\/j.annemergmed.2019.07.014.\u00a0PubMed PMID: 31515181.","DOI":"10.1016\/j.annemergmed.2019.07.014"},{"issue":"4","key":"703_CR55","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/S00127-021-02199-2","volume":"57","author":"J Van Draanen","year":"2021","unstructured":"Van Draanen J, Tsang C, Mitra S, Phuong V, Murakami A, Karamouzian M, et al. Mental disorder and opioid overdose: a systematic review. Soc Psychiatry Psychiatr Epidemiol. 2021;57(4):647. https:\/\/doi.org\/10.1007\/S00127-021-02199-2. PubMed PMID: 34796369.","journal-title":"Soc Psychiatry Psychiatr Epidemiol"},{"issue":"41","key":"703_CR56","doi-asserted-by":"publisher","first-page":"E1399","DOI":"10.1503\/cmaj.230459","volume":"195","author":"L Wang","year":"2023","unstructured":"Wang L, Hong PJ, Jiang W, Rehman Y, Hong BY, Couban RJ, et al. Predictors of fatal and nonfatal overdose after prescription of opioids for chronic pain: a systematic review and meta-analysis of observational studies. CMAJ Can Med Association J. 2023;195(41):E1399\u2013411. https:\/\/doi.org\/10.1503\/cmaj.230459. PubMed PMID: 37871953.","journal-title":"CMAJ Can Med Association J"},{"key":"703_CR57","doi-asserted-by":"publisher","unstructured":"Dinwiddie AT, Gupta S, Mattson CL, O\u2019Donnell J, Seth P. Reported non\u2013substance-related mental health disorders among persons who died of drug overdose\u2014United States, 2022. MMWR Morb Mortal Wkly Rep. 2024;73(34):747\u201353. https:\/\/doi.org\/10.15585\/MMWR.MM7334A3.\u00a0PubMed PMID: 39207934.","DOI":"10.15585\/MMWR.MM7334A3"},{"issue":"16","key":"703_CR58","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1001\/jama.2015.3474","volume":"313","author":"G D\u2019Onofrio","year":"2015","unstructured":"D\u2019Onofrio G, O\u2019Connor PG, Pantalon MV, Chawarski MC, Busch SH, Owens PH, et al. Emergency department-initiated buprenorphine\/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015;313(16):1636\u201344. 10.1001. \/JAMA.2015.3474 PubMed PMID: 25919527.","journal-title":"JAMA"},{"issue":"15","key":"703_CR59","doi-asserted-by":"publisher","first-page":"2961","DOI":"10.1007\/S11606-024-08837-0","volume":"39","author":"A Jakubowski","year":"2024","unstructured":"Jakubowski A, Singh-Tan S, Torres-Lockhart K, Lu T, Arnsten J, Southern W, et al. Addiction Consult Service and Inpatient Outcomes Among Patients with OUD. J Gen Intern Med. 2024;39(15):2961. https:\/\/doi.org\/10.1007\/S11606-024-08837-0. PubMed PMID: 39136887.","journal-title":"J Gen Intern Med"},{"issue":"12","key":"703_CR60","doi-asserted-by":"publisher","first-page":"2926","DOI":"10.1007\/s11606-024-09008-x","volume":"40","author":"R Shearer","year":"2025","unstructured":"Shearer R, Englander H, Hagedorn H, Fawole A, Laes JA, Titus H, et al. Hospital Provider\u2019s Perspectives on MOUD Initiation and Continuation After Inpatient Discharge. J Gen Intern Med. 2025;40(12):2926\u201333. 09008-X PubMed PMID: 39586949.","journal-title":"J Gen Intern Med"},{"key":"703_CR61","doi-asserted-by":"publisher","first-page":"209520","DOI":"10.1016\/J.JOSAT.2024.209520","volume":"167","author":"R Shearer","year":"2024","unstructured":"Shearer R, Hagedorn H, Englander H, Siegler T, Kibben R, Fawole A, et al. Barriers and facilitators to implementing treatment for opioid use disorder in community hospitals. J Subst Use Addict Treat. 2024;167:209520. https:\/\/doi.org\/10.1016\/J.JOSAT.2024.209520.","journal-title":"J Subst Use Addict Treat"},{"key":"703_CR62","unstructured":"Substance Abuse and Mental Health Services Administration. Financing peer recovery support: opportunities to enhance the substance use disorder workforce. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2024. Publication No. PEP23-06-07-003. [Internet]. 2024 [cited 2025 Nov 24]. Available from: https:\/\/library.samhsa.gov\/product\/financing-peer-recovery-support-opportunities-enhance-substance-use-disorder-workforce\/pep23-06-07-003."},{"issue":"1","key":"703_CR63","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/S13011-025","volume":"2025 20","author":"E Rosenfeld","year":"2025","unstructured":"Rosenfeld E, Potter S, Caputo J, Ghose SS, Nadal N, Jones CM, et al. Use of alternative payment models for substance use disorder prevention in the United States: development of a conceptual framework. Subst Abuse Treat Prev Policy. 2025;2025 20(1):1. https:\/\/doi.org\/10.1186\/S13011-025-. 00635-Z PubMed PMID: 39844326.","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"703_CR64","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/ACEM.70185","volume":"0","author":"D Hodgkin","year":"2025","unstructured":"Hodgkin D, Thomas CP, Davis MT, Wicks JJ, Greenfield SF, Meisel ZF, et al. The Financial Sustainability of Programs to Initiate Medications for Opioid Use Disorder in Emergency Department Settings. Acad Emerg Med. 2025;0:1\u20139. https:\/\/doi.org\/10.1111\/ACEM.70185. JOURNAL:15532712;WGROUP:STRING:PUBLICATION PubMed PMID: 41193942.","journal-title":"Acad Emerg Med"},{"key":"703_CR65","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.jsat.2020.02.007","volume":"112","author":"C Bogan","year":"2020","unstructured":"Bogan C, Jennings L, Haynes L, Barth K, Moreland A, Oros M, et al. Implementation of emergency department\u2013initiated buprenorphine for opioid use disorder in a rural southern state. J Subst Abuse Treat. 2020;112:73\u20138. https:\/\/doi.org\/10.1016\/j.jsat.2020.02.007. PubMed PMID: 32220414.","journal-title":"J Subst Abuse Treat"},{"issue":"2","key":"703_CR66","doi-asserted-by":"publisher","first-page":"e105","DOI":"10.1097\/ADM.0000000000000864","volume":"16","author":"D Button","year":"2022","unstructured":"Button D, Hartley J, Robbins J, Levander XA, Smith NJ, Englander H. Low-Dose Buprenorphine Initiation in Hospitalized Adults with Opioid Use Disorder: A Retrospective Cohort Analysis. J Addict Med. 2022;16(2):e105. 10. 1097\/ADM.0000000000000864 PubMed PMID: 34001775.","journal-title":"J Addict Med"},{"issue":"6","key":"703_CR67","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1001\/jamainternmed.2018.1052","volume":"178","author":"MR Lofwall","year":"2018","unstructured":"Lofwall MR, Walsh SL, Nunes EV, Bailey GL, Sigmon SC, Kampman KM, et al. Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use Disorder: A Randomized Clinical Trial. JAMA Intern Med. 2018;178(6):764\u201373. 10.1001. \/JAMAINTERNMED.2018.1052 PubMed PMID: 29799968.","journal-title":"JAMA Intern Med"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-026-00703-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-026-00703-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-026-00703-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:11:51Z","timestamp":1791911511000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13722-026-00703-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["703"],"URL":"https:\/\/doi.org\/10.1186\/s13722-026-00703-0","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"18 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was reviewed and approved by the University of California, San Diego Institutional Review Board (IRB; Protocol #811762). The study involved no interaction with human subjects and used existing, fully de-identified data. As such, it was classified as minimal risk and exempt under federal guidelines for research on existing data. Informed consent was not required. All data management procedures complied with institutional policies and the Health Insurance Portability and Accountability Act (HIPAA).","order":1,"name":"Ethics","label":"Human ethics and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"73"}}